Australia - English - Department of Health (Therapeutic Goods Administration)

indivior pty ltd - naloxone hydrochloride dihydrate, quantity: 2.44 mg (equivalent: naloxone, qty 2 mg); buprenorphine hydrochloride, quantity: 8.64 mg (equivalent: buprenorphine, qty 8 mg) - soluble film - excipient ingredients: acesulfame potassium; maltitol; polyethylene oxide; citric acid; sunset yellow fcf; hypromellose; sodium citrate; titanium dioxide; propylene glycol; purified water; industrial methylated spirit; flavour - for the treatment of opiate dependence within a framework of medical, social, and psychological treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

indivior pty ltd - buprenorphine hydrochloride, quantity: 2.16 mg (equivalent: buprenorphine, qty 2 mg); naloxone hydrochloride dihydrate, quantity: 0.61 mg (equivalent: naloxone, qty 0.5 mg) - soluble film - excipient ingredients: sunset yellow fcf; polyethylene oxide; hypromellose; maltitol; citric acid; acesulfame potassium; sodium citrate; titanium dioxide; propylene glycol; purified water; industrial methylated spirit; flavour - for the treatment of opiate dependence within a framework of medical, social, and psychological treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

indivior pty ltd - buprenorphine hydrochloride, quantity: 8.64 mg (equivalent: buprenorphine, qty 8 mg) - tablet - excipient ingredients: lactose monohydrate; mannitol; maize starch; povidone; citric acid; sodium citrate dihydrate; magnesium stearate - treatment of opiate dependence, including maintenance and detoxification, within a framework of medical, social and psychological treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

indivior pty ltd - buprenorphine hydrochloride, quantity: 2.16 mg (equivalent: buprenorphine, qty 2 mg) - tablet - excipient ingredients: lactose monohydrate; mannitol; maize starch; povidone; citric acid; sodium citrate dihydrate; magnesium stearate - treatment of opiate dependence, including maintenance and detoxification, within a framework of medical, social and psychological treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

indivior pty ltd - buprenorphine hydrochloride, quantity: 0.43 mg (equivalent: buprenorphine, qty 0.4 mg) - tablet - excipient ingredients: lactose monohydrate; mannitol; maize starch; povidone; citric acid; sodium citrate dihydrate; magnesium stearate - treatment of opiate dependence, including maintenance and detoxification, within a framework of medical, social and psychological treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

indivior pty ltd - buprenorphine, quantity: 300 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - sublocade is indicated for maintenance treatment of opioid dependence, within a framework of medical, social and psychological treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

indivior pty ltd - buprenorphine, quantity: 100 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - sublocade is indicated for maintenance treatment of opioid dependence, within a framework of medical, social and psychological treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

echo therapeutics pty ltd - buprenorphine hydrochloride, quantity: 0.216 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; mannitol; maize starch; povidone; magnesium stearate; citric acid; sodium citrate dihydrate - temgesic sublingual tablets are indicated for the short-term (not more than one week) management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain. temgesic is not recommended for use in children. temgesic does not have an approved role in opioid dependence rehabilitation programmes.

Australia - English - Department of Health (Therapeutic Goods Administration)

echo therapeutics pty ltd - buprenorphine hydrochloride, quantity: 324 microgram/ml (equivalent: buprenorphine, qty 300 microgram/ml) - injection, solution - excipient ingredients: glucose monohydrate; hydrochloric acid; water for injections - temgesic injection is indicated for the short-term (not more than one week) management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain. temgesic injection should be employed when sublingual administration is not practical e.g. pre- or peri-operatively. temgesic is not recommended for use in children. temgesic does not have an approved role in opioid dependence rehabilitation programmes.

Australia - English - Department of Health (Therapeutic Goods Administration)

indivior pty ltd - buprenorphine hydrochloride, quantity: 12.96 mg (equivalent: buprenorphine, qty 12 mg); naloxone hydrochloride dihydrate, quantity: 3.66 mg (equivalent: naloxone, qty 3 mg) - soluble film - excipient ingredients: acesulfame potassium; citric acid; maltitol solution; hypromellose; polyethylene oxide; sodium citrate; sunset yellow fcf; flavour; titanium dioxide; propylene glycol; purified water; industrial methylated spirit - treatment of opiate dependence within a framework of medical, social, and pyschological treatment.